Table 1.
Patient Cohort (IQR=Interquartile Range)
| n (%) | ||
|---|---|---|
| Total cohort | 80 (100%) | |
| Gender | Male | 61 (76.3) |
| Female | 19 (23.7) | |
| Median age years (IQR) | 71 (46–97) | |
| Median follow-up months (IQR) | 62.0 (0.0–189.0) | |
| Tumor grade (WHO 2016) | Low grade | 2 (2.5) |
| High grade | 78 (97.5) | |
| Tumor grade (WHO 1973) | G2 | 32 (40.0) |
| G3 | 48 (60.0) | |
| Lymphovascular invasion | Yes | 2 (2.5) |
| No/NA | 78 (97.5) | |
| Concomitant CIS | Yes | 28 (35.0) |
| No/NA | 52 (65.0) | |
| Adjuvant instillation | Yes | 41 (51.2) |
| No | 39 (48.8) | |
| Median follow-up months (IQR) | 62.0 (0.0–189.0) | |
| Recurrence-free survival (RFS) | Recurrence | 41 (51.2) |
| No recurrence | 39 (48.8) | |
| Progression-free survival (PFS) | Progression | 6 (7.5) |
| No progression | 74 (92.5) | |
| Cancer-specific survival (CSS) | Cancer-specific death | 16 (20.0) |
| Others | 64 (80.0) | |
| Overall survival (OS) | Death | 36 (45.0) |
| Alive | 44 (55.0) |
Abbreviations: IQR, interquartile range; CIS, carcinoma in situ; WHO, World Health Organization; NA, not available.